The Drug Supply Chain and Pricing: From Manufacturer to Net Revenue

Introduction

The path from drug manufacturer to patient involves a chain of intermediaries, each playing a specific role and extracting economic value. For healthcare bankers, the supply chain matters because it determines how much of the list price actually reaches the manufacturer as net revenue, it creates several distinct business models (wholesalers, PBMs, specialty pharmacies) that are active M&A targets, and it is increasingly subject to political and regulatory scrutiny.

Wholesalers/Distributors

Three companies dominate pharmaceutical distribution in the US, collectively handling over 90% of drug shipments from manufacturers to pharmacies and hospitals:

Wholesalers purchase drugs from manufacturers (at WAC minus a small distribution fee, typically 1-3%) and sell them to retail pharmacies, hospitals, and other dispensing sites. Their margins are thin (1-3% operating margin) but their revenue is enormous because they handle nearly every prescription drug sold in the US.

Buy-and-Hold vs. Fee-for-Service Distribution

Pharmaceutical wholesalers historically operated on a buy-and-hold model, purchasing inventory at one price and selling at a higher price, profiting from the spread and from price inflation during the holding period. The industry has largely shifted to a fee-for-service model where wholesalers earn a negotiated distribution fee (typically 1-3% of WAC) rather than profiting from inventory speculation. This shift was driven by the move toward just-in-time inventory management and manufacturer pressure to control distribution costs.

Pharmacy Benefit Managers (PBMs)

PBMs sit between drug manufacturers, health insurers, and pharmacies, managing prescription drug benefits for health plans. The three largest PBMs manage approximately 80% of US prescription claims:

PBMs perform several functions: they negotiate rebates from manufacturers in exchange for formulary placement, process prescription claims, manage pharmacy networks, and administer mail-order pharmacies. Their primary revenue driver is the spread between what they charge health plans and what they pay pharmacies, plus the rebates negotiated from manufacturers (a portion of which they retain).

Specialty Pharmacies

Specialty pharmacies dispense high-cost, complex medications (biologics, oncology therapies, rare disease treatments) that require special handling, patient support, and clinical monitoring. The specialty pharmacy market has grown rapidly (now over $350 billion in annual revenue) because the pharmaceutical pipeline is increasingly focused on specialty and biologic products.

Major specialty pharmacy operators include CVS Specialty, Accredo (Express Scripts/Cigna), and Optum Specialty Pharmacy, mirroring the PBM consolidation pattern. This vertical integration (PBM + specialty pharmacy + insurance under one corporate umbrella) has drawn regulatory scrutiny.

The 340B Drug Pricing Program, which requires manufacturers to provide outpatient drugs at significant discounts to covered entities (safety-net hospitals, federally qualified health centers), has grown into a $66 billion+ annual market that adds complexity to the supply chain.

Covered entities purchase drugs at the 340B ceiling price (which can be 25-60% below WAC) but may receive full reimbursement from commercial insurers. The resulting "340B spread" has made the program a significant revenue source for covered entities and a significant cost driver for manufacturers.

GPOs aggregate the purchasing volume of hospitals, health systems, and other institutional buyers to negotiate volume-based discounts from manufacturers and distributors. The largest GPOs (Vizient, Premier, HealthTrust) represent thousands of hospitals and negotiate pricing across pharmaceuticals, medical devices, and supplies.

For pharma companies, GPO contracts determine institutional pricing and access. A drug that is not on a GPO contract may be effectively locked out of the hospital market. GPO fees (typically 1-3% of contract value, paid by the manufacturer) represent an additional GTN deduction that affects net revenue calculations.

The drug supply chain itself generates significant IB activity. Vertical integration transactions (CVS acquiring Aetna for $69 billion, Cigna merging with Express Scripts for $67 billion, UnitedHealth building Optum through multiple acquisitions) have reshaped the healthcare landscape. These transactions are among the largest in healthcare M&A history. Horizontal consolidation among wholesalers, specialty pharmacies, and pharmacy chains continues, and emerging areas like specialty pharmacy platforms, drug distribution technology companies, and transparency/analytics tools attract both strategic and financial buyers.

For healthcare bankers, the supply chain is both a sector to cover (advising supply chain companies on M&A) and a factor to model (understanding how supply chain dynamics affect pharma company revenues and margins).

The supply chain mechanics interact directly with the IRA's drug pricing provisions, which overlay government price negotiation onto the existing supply chain structure.